![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 12
Zeitschriftenartikel
Metzgeroth, G.; Schwaab, J.; Naumann, N.; Haferlach, C.; Jawhar, M.; Horny, H.-P.; Dirk, J.; Kratz-Albers, K.; Krämer, D.; Mayer, S.; Storch, N.; Burchert, A.; Haferlach, T.; Cross, N. C. P.; Hofmann, W.-K.; Fabarius, A. und Reiter, A.
(2017):
Clinical characteristics and treatment with ruxolitinib in patients with PCM1-JAK2 and BCR-JAK2 positive myeloid/lymphoid neoplasms with eosinophilia.
In: Oncology Research and Treatment, Bd. 40: S. 196
Jawhar, M.; Schwaab, J.; Schnittger, S.; Meggendorfer, M.; Pfirrmann, Markus; Sotlar, K.; Horny, H. P.; Metzgeroth, G.; Kluger, S.; Naumann, N.; Haferlach, C.; Haferlach, T.; Valent, P.; Hofmann, W. K.; Fabarius, A.; Cross, N. C. und Reiter, A.
(2016):
Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.
In: Leukemia, Bd. 30, Nr. 1: S. 136-143
Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G. und Reiter, A.
(2016):
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
In: Leukemia, Bd. 30, Nr. 12: S. 2342-2350
Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H. P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C.; Fabarius, A.; Hofmann, W. K.; Valent, P.; Metzgeroth, G. und Reiter, A.
(2016):
Splenomegaly and elevated alkaline phosphatase are strong and independent adverse prognostic markers in patients with systemic mastocytosis.
In: Haematologica, Bd. 101: S. 559
Jawhar, M.; Schwaab, J.; Meggendorfer, M.; Naumann, N.; Kluger, S.; Horny, H.-P.; Sotlar, K.; Haferlach, T.; Fabarius, A.; Hofmann, W.-K.; Reiter, A. und Metzgeroth, G.
(2016):
Mast cell leukemia: clinical heterogeneity, molecular aberrations and prognostic factors.
In: Oncology Research and Treatment, Bd. 39: S. 24
Naumann, N.; Jawhar, M.; Schwaab, J.; Metzgeroth, G.; Khaled, N.; Horny, H.-P.; Sotlar, K.; Valent, P.; Haferlach, C.; Göhring, G.; Schlegelberger, B.; Meggendorfer, M.; Cross, N. C. P.; Hofmann, W. K.; Reiter, A. und Fabarius, A.
(2016):
Incidence and prognostic impact of cytogenetic aberrations in systemic mastocytosis.
In: Oncology Research and Treatment, Bd. 39: S. 25
Jawhar, M.; Schwaab, J.; Hausmann, D.; Clemens, J.; Naumann, N.; Henzler, T.; Horny, H.-P.; Sotlar, K.; Schoenberg, S. O.; Cross, N. C. P.; Fabarius, A.; Hofmann, W.-K.; Valent, P.; Metzgeroth, G. und Reiter, A.
(2016):
Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis.
In: Oncology Research and Treatment, Bd. 39: S. 232
Schwaab, J.; Schnittger, S.; Sotlar, K.; Walz, C.; Fabarius, A.; Pfirrmann, Markus; Kohlmann, A.; Grossmann, V.; Meggendorfer, M.; Horny, H. P.; Valent, P.; Jawhar, M.; Teichmann, M.; Metzgeroth, G.; Erben, P.; Ernst, T.; Hochhaus, A.; Haferlach, T.; Hofmann, W. K.; Cross, N. C. und Reiter, A.
(2013):
Comprehensive mutational profiling in advanced systemic mastocytosis.
In: Blood, Bd. 122, Nr. 14: S. 2460-2466
Rohrbacher, M.; Berger, Ursula; Hochhaus, A.; Metzgeroth, G.; Adam, K.; Lahaye, T.; Saußele, Susanne; Muller, M. C.; Hasford, Joerg; Heimpel, H. und Hehlmann, R.
(2009):
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany.
In: Leukemia, Bd. 23, Nr. 3: S. 602-604
Maywald, O.; Pfirrmann, Markus; Berger, Ursula; Breitscheidel, L.; Gratwohl, A.; Kolb, H. J.; Beelen, D. W.; Tobler, A.; Metzgeroth, G.; Gnad, S. U.; Hochhaus, A.; Hasford, Joerg; Hehlmann, R. und Reiter, A.
(2006):
Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.
In: Leukemia, Bd. 20, Nr. 3: S. 477-484
Berger, Ursula; Engelich, G.; Maywald, O.; Pfirrmann, Markus; Hochhaus, A.; Reiter, A.; Metzgeroth, G.; Gnad, U.; Hasford, Joerg; Heinze, B.; Heimpel, H.; Hossfeld, D. K.; Kolb, H.-J.; Löffler, H.; Pralle, H.; Queisser, W. und Hehlmann, R.
(2003):
Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha.
In: Leukemia, Bd. 17, Nr. 9: S. 1820-1826
Hehlmann, R.; Berger, Ursula; Pfirrmann, Markus; Hochhaus, A.; Metzgeroth, G.; Maywald, O.; Hasford, Joerg; Reiter, A.; Hossfeld, D. K.; Kolb, H. J.; Löffler, H.; Pralle, H.; Queisser, W.; Griesshammer, M.; Nerl, C.; Kuse, R.; Tobler, A.; Eimermacher, H.; Tichelli, A.; Aul, C.; Wilhelm, M.; Fischer, J. T.; Perker, M.; Scheid, C.; Schenk, M.; Weiss, J.; Meier, C. R.; Kremers, S.; Labedzki, L.; Schmeiser, T.; Lohrmann, H. P.; Heimpel, H.; Kolb, H.-J. und Lohrmann, H.-P.
(2003):
Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
In: Leukemia, Bd. 17, Nr. 8: S. 1529-1537